eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
    Irinotecan hydrochloride
  4. Intervention
  5. Resource Description
    There is no current standard treatment for recurrent/refractory medulloblastoma/PNET. Recurrent/refractory medulloblastoma/PNET is difficult to treat successfully. Previous studies have shown that the combination of the medicines temozolomide and irinotecan have activity against recurrent medulloblastoma/PNET. This study will use temozolomide and irinotecan to try to improve or slow the growth of recurrent/refractory medulloblastoma/PNET. Some of the participants in this study will also receive the medicine bevacizumab. Bevacizumab works differently than the medications temozolomide and irinotecan. Adding bevacizumab to treatment with temozolomide and irinotecan is experimental.
  6. Additional Name
    Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
  7. Contact
    Berenberg, Jeffrey
  8. PI
    Wilkinson, Robert, M.D.
  9. Topic
  10. Study Population
    Patient Age: Patients must be less than or equal to 21 years of age .For patients with recurrent or refractory medulloblastoma/PNET tumor
  11. Funded by
    Children's Oncology Group
  12. Phase
    Phase 2 clinical trial
  13. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016